CELC
Celcuity Inc. Common Stock
stockNASDAQ
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 79.64 | 2026-09-28 | -9.24% | -4.685 |
| 1M | 95.70 | 2026-09-04 | -24.47% | 1.806 |
| 3M | 108.58 | 2026-07-06 | -33.43% | 1.369 |
| 6M | 114.22 | 2026-04-06 | -36.72% | 1.013 |
| 1Y | 50.51 | 2025-10-03 | +43.10% | 1.248 |
| 2Y | 15.04 | 2024-10-04 | +380.58% | — |
| 5Y | 17.24 | 2021-10-04 | +319.26% | 0.857 |
Celcuity Inc. Common Stock (NASDAQ:CELC) stock price today is $72.28, and today's volume is 1,421,129. CELC is down 3.793% today. The 30 day average volume is 920,155. CELC market cap is $3.54B with 48.93M shares outstanding.